Rockwell Medical, Inc. (NASDAQ:RMTI) Short Interest Down 13.0% in February

Rockwell Medical, Inc. (NASDAQ:RMTI) was the recipient of a significant decrease in short interest in February. As of February 15th, there was short interest totalling 438,800 shares, a decrease of 13.0% from the January 31st total of 504,200 shares. Based on an average trading volume of 414,700 shares, the short-interest ratio is currently 1.1 days. Approximately 1.6% of the company’s stock are short sold.

Rockwell Medical Price Performance

Shares of NASDAQ:RMTI traded down $0.02 during trading hours on Thursday, hitting $1.63. 6,320 shares of the company’s stock traded hands, compared to its average volume of 250,504. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.00 and a current ratio of 2.41. The company’s fifty day simple moving average is $1.98 and its two-hundred day simple moving average is $2.72. Rockwell Medical has a 52 week low of $1.35 and a 52 week high of $5.15. The company has a market cap of $52.68 million, a price-to-earnings ratio of -32.60 and a beta of 1.39.

Institutional Trading of Rockwell Medical

Several institutional investors and hedge funds have recently bought and sold shares of RMTI. Concurrent Investment Advisors LLC acquired a new stake in shares of Rockwell Medical during the third quarter worth approximately $40,000. Verus Capital Partners LLC purchased a new position in shares of Rockwell Medical during the 3rd quarter valued at $51,000. Raymond James Financial Inc. acquired a new stake in Rockwell Medical during the fourth quarter valued at $28,000. Two Sigma Securities LLC acquired a new position in Rockwell Medical in the 4th quarter worth about $33,000. Finally, Barclays PLC bought a new stake in shares of Rockwell Medical in the 3rd quarter valued at approximately $90,000. Institutional investors and hedge funds own 23.31% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently commented on RMTI shares. HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of Rockwell Medical in a research report on Monday, December 23rd. StockNews.com lowered Rockwell Medical from a “buy” rating to a “hold” rating in a research report on Friday, December 20th. Rodman & Renshaw began coverage on shares of Rockwell Medical in a report on Thursday, November 14th. They set a “buy” rating and a $5.00 price target for the company. Finally, RODMAN&RENSHAW upgraded shares of Rockwell Medical to a “strong-buy” rating in a research report on Thursday, November 14th.

About Rockwell Medical

Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.